Omar Saavedra
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Evolving landscape of targeted therapies in early phase clinical trials.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 04, 2026
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab.
Journal: JCO precision oncology
Published: August 23, 2024
First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 01, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Journal: Nature
Published: March 01, 2024
'Puzzle' cutting guides for minimally invasive Le Fort I: technical note.
Journal: International journal of oral and maxillofacial surgery
Published: January 31, 2024
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours.
Journal: BMJ oncology
Published: November 07, 2023
Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors.
Journal: Cancer medicine
Published: October 16, 2023
Safety and efficiency of discharge to home hospitalization directly after emergency department care of patients with acute heart failure.
Journal: Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias
Published: June 23, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials.
Journal: Med (New York, N.Y.)
Published: January 22, 2023
Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients.
Journal: Oral oncology
Published: September 28, 2022
Response to "Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias".
Journal: Cancer treatment reviews
Published: September 06, 2022
Last Updated: 09/26/2026